Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents.

[1]  M. Böhm,et al.  Positive Inotropic Effects Due to Partial Agonistic Activity of the β‐Adrenoceptor Antagonist Celiprolol Following Amplification of cAMP Formation in Failing Human Myocardium , 1992, Journal of Cardiovascular Pharmacology.

[2]  Eric J. Eichhorn.  The paradox of β-adrenergic blockade for the management of congestive heart failure , 1992 .

[3]  S. Hohnloser,et al.  Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias. , 1992, American heart journal.

[4]  L. Mestroni,et al.  Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. , 1992, The Journal of clinical investigation.

[5]  M. Michel,et al.  Spare Receptors for β‐Adrenoceptor-Mediated Positive Inotropic Effects of Catecholamines in the Human Heart , 1992, Journal of cardiovascular pharmacology.

[6]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[7]  J. Port,et al.  Receptor pharmacology of carvedilol in the human heart. , 1992, Journal of cardiovascular pharmacology.

[8]  F. Marumo,et al.  Effect of long-term carvedilol therapy on renal function in essential hypertension. , 1992, Journal of cardiovascular pharmacology.

[9]  D. Renlund,et al.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. , 1991, Circulation.

[10]  D. Renlund,et al.  Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. , 1991, Circulation.

[11]  D. Renlund,et al.  Long-term (2 year) beneficial effects of beta-adrenergic blockade with bucindolol in patients with idiopathic dilated cardiomyopathy. , 1991, Journal of the American College of Cardiology.

[12]  D. Modersohn,et al.  Acute haemodynamic profile of celiprolol in patients with coronary heart disease and hypertension: a double-blind comparison with metoprolol. , 1991, European heart journal.

[13]  J. Port,et al.  Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium , 1991 .

[14]  A. Lenarda,et al.  Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy , 1991 .

[15]  E. Hammond,et al.  Comparison of sympathetic innervation of failing and nonfailing human hearts by quantitative evaluation of catecholamine fluorescence , 1991 .

[16]  M. Bristow,et al.  Xamoterol has agonist activity in end-stage failing human heart , 1991 .

[17]  S. G. Pollock,et al.  Usefulness of bucindolol in congestive heart failure. , 1990, The American journal of cardiology.

[18]  U. Tebbe,et al.  Hemodynamic Effects of Nebivolol at Rest and on Exertion in Patients with Heart Failure , 1990, Angiology.

[19]  H. Ikram,et al.  Xamoterol in severe heart failure , 1990, The Lancet.

[20]  J. Port,et al.  Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. , 1990, Circulation.

[21]  P. Grayburn,et al.  Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. , 1990, Circulation.

[22]  R. Hershberger,et al.  Mechanism of Action of Bucindolol in Human Ventricular Myocardium , 1990, Journal of cardiovascular pharmacology.

[23]  D. Renlund,et al.  Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.

[24]  D. Kazierad,et al.  Dilevalol: An Overview of Its Clinical Pharmacology and Therapeutic Use in Hypertension , 1990, Pharmacotherapy.

[25]  K. Jakobs,et al.  Localization of a "postreceptor" defect in human dilated cardiomyopathy. , 1989, The American journal of cardiology.

[26]  K Caidahl,et al.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.

[27]  J. Port,et al.  Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. , 1989, Molecular pharmacology.

[28]  H. Valantine,et al.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. , 1989, Circulation.

[29]  R. Walsh,et al.  Effect of intravenous metoprolol on left ventricular performance in Q-wave acute myocardial infarction. , 1989, The American journal of cardiology.

[30]  R. Hershberger,et al.  Alpha-1 adrenergic receptors in the nonfailing and failing human heart. , 1988, The Journal of pharmacology and experimental therapeutics.

[31]  D. Ferguson,et al.  Cardiopulmonary baroreflexes fail to modulate sympathetic responses during isometric exercise in humans: direct evidence from microneurographic studies. , 1988, Journal of the American College of Cardiology.

[32]  W. Schmitz,et al.  INCREASE IN MYOCARDIAL Gi-PROTEINS IN HEART FAILURE , 1988, The Lancet.

[33]  P. Insel,et al.  Molecular mechanism of β‐adrenergic receptor blockers with intrinsic sympathomimetic activity , 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  R. Jones,et al.  Hemodynamic Effects of Labetalol in Patients with Combined Hypertension and Left Ventricular Failure , 1988, Journal of cardiovascular pharmacology.

[35]  W. Baumgartner,et al.  Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. , 1988, The Journal of clinical investigation.

[36]  R. Reneman,et al.  Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. , 1988, Journal of cardiovascular pharmacology.

[37]  M. Packer,et al.  Neurohormonal interactions and adaptations in congestive heart failure. , 1988, Circulation.

[38]  Pruss Tp,et al.  Celiprolol--overview of 6 years of clinical trials experience. , 1988 .

[39]  P. Lund-johansen.  Hemodynamic effects of beta-blocking compounds possessing vasodilating activity: a review of labetalol, prizidilol, and dilevalol. , 1988, Journal of cardiovascular pharmacology.

[40]  K. Lurie,et al.  6-Hydroxydopamine mediated cardiotoxicity in rabbits. , 1988, The American journal of cardiovascular pathology.

[41]  J. Vincent,et al.  REDUCTION OF STRESS/ CATECHOLAMINE-INDUCED CARDIAC NECROSIS BY BETA1-SELECTIVE BLOCKADE , 1987, The Lancet.

[42]  M. Sole,et al.  Acute Hemodynamic and Neurohumoral Effects of Pindolol: A β‐Adrenoceptor Antagonist with High Intrinsic Sympathomimetic Activity in Patients with Dilated Cardiomyopathy , 1987, Journal of cardiovascular pharmacology.

[43]  J. Anderson,et al.  Long-term experience with sotalol in the treatment of complex ventricular arrhythmias. , 1987, American heart journal.

[44]  J. Rosenbaum,et al.  Effects of adrenergic receptor antagonists on cardiac morphological and functional alterations in rats harboring pheochromocytoma. , 1987, The Journal of pharmacology and experimental therapeutics.

[45]  D. Goldstein,et al.  Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. , 1987, The New England journal of medicine.

[46]  B. J. Clark,et al.  Is the ISA of pindolol beta 2-adrenoceptor selective? , 1987, British journal of clinical pharmacology.

[47]  A. Dupont,et al.  Effect of Carvedilol on Ambulatory Blood Pressure, Renal Hemodynamics, and Cardiac Function in Essential Hypertension , 1987, Journal of cardiovascular pharmacology.

[48]  K. Strein,et al.  Pharmacological Profile of Carvedilol, a Compound with &bgr;‐Blocking and Vasodilating Properties* , 1987, Journal of cardiovascular pharmacology.

[49]  R. van der Does,et al.  Acute Hemodynamic Effects of the Vasodilating and &bgr;‐Blocking Agent Carvedilol in Comparison to Propranolol , 1987, Journal of cardiovascular pharmacology.

[50]  P. Binkley,et al.  Hemodynamic-inotropic response to beta-blocker with intrinsic sympathomimetic activity in patients with congestive cardiomyopathy. , 1986, Circulation.

[51]  R. Hetzer,et al.  Regional Distribution of β‐Adrenoceptors in the Human Heart: Coexistence of Functional β1 and β2-Adrenoceptors in Both Atria and Ventricles in Severe Congestive Cardiomyopathy , 1986 .

[52]  M. Pfisterer,et al.  Acute Hemodynamic Effects of Bisoprolol, a New β1, Selective Adrenoreceptor Blocking Agent, in Patients with Coronary Artery Disease , 1986 .

[53]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[54]  A. Kaumann,et al.  Mode of action of (‐)‐pindolol on feline and human myocardium , 1986, British journal of pharmacology.

[55]  W. Shen,et al.  A Comparison of the Effects of β‐Blockers With and Without Intrinsic Sympathomimetic Activity on Hemodynamics and Left Ventricular Function at Rest and During Exercise in Patients with Coronary Artery Disease , 1986 .

[56]  P. Korner,et al.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.

[57]  C. Rose,et al.  Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. , 1985, The Journal of clinical investigation.

[58]  R. Gunnar,et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.

[59]  N. Kantrowitz,et al.  Beta-adrenergic function in heart muscle disease and heart failure. , 1985, Journal of molecular and cellular cardiology.

[60]  E. Carmeliet.  Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.

[61]  M. A. Mian,et al.  The sympathomimetic activity of (±)-pindolol at β1- and β2-adrenoceptor sites , 1985 .

[62]  J S Janicki,et al.  Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. , 1985, The American journal of cardiology.

[63]  R. V. Van Inwegen,et al.  Effects of celiprolol (REV 5320), a new cardioselective beta-adrenoceptor antagonist, on in vitro adenylate cyclase, alpha- and beta-adrenergic receptor binding and lipolysis. , 1984, Archives internationales de pharmacodynamie et de therapie.

[64]  J. Harting,et al.  Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs. , 1984, Journal of cardiovascular pharmacology.

[65]  P. Vanhoutte,et al.  Pharmacology of bucindolol in isolated canine vascular smooth muscle. , 1984, The Journal of pharmacology and experimental therapeutics.

[66]  K. Swedberg,et al.  Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. , 1984, The American journal of cardiology.

[67]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[68]  C. Rose,et al.  Reduced aortocoronary sinus extraction of epinephrine in patients with left ventricular failure secondary to long-term pressure or volume overload. , 1983, Circulation.

[69]  J. Wallin,et al.  Labetalol. Current research and therapeutic status. , 1983, Archives of internal medicine.

[70]  F. Waagstein,et al.  Beta-blockers in dilated cardiomyopathies: they work. , 1983, European heart journal.

[71]  J. Cohn,et al.  Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. , 1982, American heart journal.

[72]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[73]  S. Taylor,et al.  Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful? , 1982, The New England journal of medicine.

[74]  S. Taylor,et al.  HAEMODYNAMIC EFFECTS OF BETA-BLOCKADE IN ISCHAEMIC HEART FAILURE , 1981, The Lancet.

[75]  K. Swedberg,et al.  Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. , 1980, British heart journal.

[76]  R. Lefkowitz,et al.  A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. , 1980, Molecular pharmacology.

[77]  W. Nayler,et al.  Uptake of catecholamines by human cardiac muscle in vitro. , 1979, British heart journal.

[78]  D. Richards,et al.  Clinical pharmacology of labetalol. , 1979, British journal of clinical pharmacology.

[79]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[80]  R. Miller,et al.  Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. , 1977, The New England journal of medicine.

[81]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[82]  B. Åblad,et al.  Pharmacological studies of two new cardioselective adrenergic beta-receptor antagonists. , 1973, Life sciences. Pt. 1: Physiology and pharmacology.

[83]  D. Reichenbach,et al.  Catecholamines and cardiomyopathy: The pathogenesis and potential importance of myofibrillar degeneration , 1970 .

[84]  P. Somani,et al.  Blockade of cardiac effects of isoproterenol by the stereoisomers of sotalol. , 1969, European journal of pharmacology.

[85]  J. R. Schmid,et al.  A comparison of the antiarrhythmic actions of two new synthetic compounds, iproveratril and MJ 1999, with quinidine and pronethalol. , 1967, The Journal of pharmacology and experimental therapeutics.

[86]  S. Stephen.  Unwanted effects of propranolol. , 1966, The American journal of cardiology.

[87]  P. M. Lish,et al.  Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. , 1965, The Journal of pharmacology and experimental therapeutics.

[88]  W. Osler.  A Treatise on the Principles and Practice of Medicine; Designed for the Use of Practitioners and Students of Medicine , 1867, Atlanta medical and surgical journal.